

# Ilaris (canakinumab) — HCPCS J0638

CARECOST ESTIMATE · BILLING CHEAT SHEET

**Novartis Pharmaceuticals** 150 mg lyophilized SDV (reconstitute to 150 mg/mL) · also 150 mg/mL liquid SDV

SC injection every 4 or 8 weeks (indication-dependent) **Reviewed:** May 22, 2026 **ASP:** Q2 2026

<b>HCPCS</b> <b>J0638</b> 1 mg = 1 unit	<b>CAPS ADULT DOSE</b> <b>150 units</b> 150 mg SC q8wk (>40 kg)	<b>ADMIN CPT</b> <b>96372</b> SC therapeutic inj, non-chemo	<b>MODIFIER</b> <b>JW/JZ</b> Waste typical in pediatric mg/kg dosing	<b>MEDICARE ASP+6%</b> <b>\$149.574</b> /mg · \$22,436.10/150 mg dose
---	---	---	--	---

CODES & NDC	
CODE	DETAIL
J0638	"Injection, canakinumab, 1 mg" (permanent code)
NDC	0078-0582-61 — 150 mg lyophilized powder SDV (reconstitute with 1 mL SWFI → 150 mg/mL)
NDC	0078-0734-61 — 150 mg/mL solution for injection SDV (ready-to-use; no reconstitution)
VIAL	Both presentations are 150 mg single-dose; preservative-free
MANUFACTURER	Novartis Pharmaceuticals Corporation (labeler 0078)
INDICATIONS	CAPS (2009) · SJIA (5/2013) · TRAPS, HIDS/MKD, FMF (9/2016) · AOSD/Still's (6/16/2020)

ICD-10 BY INDICATION	
CODE	INDICATION
M04.2	Cryopyrin-associated periodic syndrome (CAPS) — FCAS, MWS, NOMID/CINCA
M04.1	Periodic fever syndromes — TRAPS (TNFRSF1A)
E85.0	Familial Mediterranean fever (MEFV)
E78.72	Mevalonate kinase deficiency (HIDS/MKD)
M08.20	Systemic juvenile idiopathic arthritis (SJIA)
M06.1	Adult-onset Still's disease (AOSD)

DOSING BY INDICATION (ALL SC)		
INDICATION	DOSE	INTERVAL
CAPS, adult/ped >40 kg	150 mg	q8wk
CAPS, ped 15–40 kg	2 mg/kg (titrate to 3 mg/kg)	q8wk
TRAPS/HIDS/FMF, >40 kg	150 mg (titrate to 300 mg)	q4wk
TRAPS/HIDS/FMF, ped 7.5–≤40 kg	2 mg/kg (titrate to 4 mg/kg)	q4wk
SJIA / AOSD, ≥7.5 kg	4 mg/kg (max 300 mg)	q4wk

**Pediatric mg/kg dosing produces routine partial-vial waste from 150 mg SDV — JW required on the discard line.**

TOP DENIALS (IN ORDER)
<ul style="list-style-type: none"> <li><b>#1 Genetic test missing</b> for hereditary periodic fever: NLRP3 (CAPS), MEFV (FMF), MVK (HIDS), TNFRSF1A (TRAPS) — submit lab report</li> <li>Wrong admin code (96365 IV instead of 96372 SC) — resubmit with 96372</li> <li>Wrong unit count (vials instead of mg) — bill <i>mg administered</i>, not vials</li> <li>JW omitted on pediatric mg/kg dose — bill discard on separate line</li> <li>TB / HepB screening not documented (required pre-treatment)</li> <li>SJIA: prior NSAID + corticosteroid trial not documented (UHC/Aetna step therapy)</li> <li>AOSD: Yamaguchi or Fautrel criteria not in chart notes</li> </ul>

MEDICARE REIMBURSEMENT (Q2 2026)	
ITEM	AMOUNT
J0638 per 1 mg unit (ASP+6%)	<b>\$149.574</b>
CAPS adult 150 mg dose	<b>\$22,436.10</b>
CAPS adult annual (q8wk × ~6.5 doses)	~\$145,834.65
FMF adult 150 mg q4wk annual (13 doses)	~\$291,669.30
SJIA 25 kg child (100 mg q4wk × 13)	~\$194,446.20 administered + JW reimbursable

## ADMINISTRATION & MODIFIERS

CODE	WHEN
96372	<b>Primary admin code.</b> "Therapeutic SC/IM injection, non-chemo" — bill every administration
96401	<b>NOT appropriate</b> — canakinumab is non-chemotherapy biologic
96365/96401	<b>NOT appropriate</b> — SC injection, not IV infusion

**JW:** common in pediatric mg/kg dosing (e.g., 25 kg SJIA = 100 mg → 50 mg JW from 150 mg vial). **JZ:** use when full 150 mg vial administered with no waste (adult CAPS / TRAPS / FMF / HIDS).

## SITE OF CARE

SETTING	POS	NOTES
Rheumatology office	11	<b>Preferred</b> — standard for periodic fevers
Pediatric rheum / specialty clinic	11	SJIA / pediatric CAPS standard
Hospital outpatient	22	Acceptable; commercial payers may steer to office
Home self-admin	12	Uncommon — lyophilized vial requires reconstitution; liquid 0078-0734 enables home use with training

## PATIENT ASSISTANCE — NOVARTIS

- **Novartis Patient Assistance Foundation (NPAF):** 1-800-277-2254 — free product for uninsured / underinsured meeting income criteria (501(c)(3))
- **Ilaris Companion Program / Novartis Patient Support:** benefits investigation, PA assistance, appeals, nurse education
- **Ilaris Co-Pay Program:** commercial copay support — **excludes Medicare/Medicaid/federal**
- **Foundations (Medicare):** Patient Advocate Foundation, HealthWell, NORD — verify open autoinflammatory funds
- **Web:** [ilaris.com](http://ilaris.com) · [patientassistancenow.com](http://patientassistancenow.com)

**WARNINGS & PRECAUTIONS:** Serious infections (esp. bacterial); evaluate for TB before start & periodically. Hypersensitivity reactions. Avoid live vaccines. Macrophage activation syndrome (MAS) reported in SJIA/AOSD — vigilant monitoring required.